ResMed (MEX:RMD) Cyclically Adjusted FCF per Share: MXN106.14 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:RMD ResMed Inc MEX:RMD
98 GF Score
Price MXN4,082.00
GF Value MXN4,760.23
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is ResMed Cyclically Adjusted FCF per Share?

ResMed MEX:RMD 98 Cyclically Adjusted FCF per Share is MXN106.14 as of Jun. 2026. GuruFocus rates MEX:RMD with a GF Score™ of 98/100 and a GF Value™ of MXN4,760.23 (Modestly Undervalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

ResMed's adjusted free cash flow per share for the three months ended in Jun. 2026 was MXN47.784. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is MXN106.14 for the trailing ten years ended in Jun. 2026.

During the past 12 months, ResMed's average Cyclically Adjusted FCF Growth Rate was 16.10% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 19.30% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 14.10% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 13.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of ResMed was 100.00% per year. The lowest was 8.30% per year. And the median was 19.70% per year.

As of today (2026-09-04), ResMed's current stock price is MXN4082.00. ResMed's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was MXN106.14. ResMed's Cyclically Adjusted Price-to-FCF of today is 38.46.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of ResMed was 91.58. The lowest was 32.28. And the median was 51.55.


ResMed  (MEX:RMD) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

ResMed's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=4082.00/106.14
=38.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of ResMed was 91.58. The lowest was 32.28. And the median was 51.55.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


ResMed Cyclically Adjusted FCF per Share Related Terms


ResMed Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for ResMed's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ResMed Cyclically Adjusted FCF per Share Chart

ResMed Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 66.76 65.37 86.79 95.72 106.14

ResMed Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 95.72 101.38 101.61 104.84 106.14

MEX:RMD vs MDLN, WST, BDX: Cyclically Adjusted FCF per Share Comparison

For the Medical Instruments & Supplies subindustry, ResMed's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ResMed Cyclically Adjusted Price-to-FCF vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ResMed's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where ResMed's Cyclically Adjusted Price-to-FCF falls into.


MEX:RMD
98GF Score
ResMed Inc MEX:RMD
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ResMed Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ResMed's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=47.784/333.9520*333.9520
=47.784

Current CPI (Jun. 2026) = 333.9520.

ResMed Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 9.418 241.428 13.027
201612 14.956 241.432 20.687
201703 6.677 243.801 9.146
201706 15.157 244.955 20.664
201709 9.576 246.819 12.957
201712 15.591 246.524 21.120
201803 16.907 249.554 22.625
201806 14.937 251.989 19.795
201809 4.223 252.439 5.587
201812 14.827 251.233 19.709
201903 16.484 254.202 21.655
201906 15.581 256.143 20.314
201909 18.725 256.759 24.355
201912 5.445 256.974 7.076
202003 33.412 258.115 43.229
202006 48.818 257.797 63.239
202009 18.940 260.280 24.301
202012 17.912 260.474 22.965
202103 23.478 264.877 29.601
202106 26.563 271.696 32.650
202109 -13.644 274.310 -16.611
202112 25.139 278.802 30.112
202203 8.845 287.504 10.274
202206 6.442 296.311 7.260
202209 1.680 296.808 1.890
202212 12.825 296.797 14.431
202303 30.737 301.836 34.007
202306 23.076 305.109 25.257
202309 28.985 307.789 31.449
202312 28.563 306.746 31.096
202403 42.650 312.332 45.602
202406 51.376 314.175 54.610
202409 40.812 315.301 43.226
202412 40.324 315.605 42.668
202503 77.107 319.799 80.519
202506 64.656 322.561 66.939
202509 51.392 324.800 52.840
202512 37.542 324.054 38.689
202603 63.673 330.213 64.394
202606 47.784 333.952 47.784

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of MXN106.14 mean?
ResMed (MEX:RMD) has a Cyclically Adjusted FCF per Share of MXN106.14 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on ResMed and its competitors.
Is ResMed's Cyclically Adjusted FCF per Share too high?
ResMed's current Cyclically Adjusted FCF per Share is MXN106.14. Overall, ResMed has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ResMed's Cyclically Adjusted FCF per Share compare to MDLN and WST?
ResMed's Cyclically Adjusted FCF per Share of MXN106.14 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted FCF per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on ResMed and its competitors. ResMed's current Cyclically Adjusted FCF per Share is MXN106.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ResMed stock overvalued right now?
Based on GuruFocus' analysis, ResMed (MEX:RMD) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN4,760.23, compared to a current price of MXN4,082.00 — trading 14.2% below its estimated fair value. The current Cyclically Adjusted FCF per Share is MXN106.14. ResMed's overall GF Score™ is 98/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For ResMed (MEX:RMD), the current Cyclically Adjusted FCF per Share is MXN106.14 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ResMed (MEX:RMD) Overvalued in 2026?

Based on GuruFocus' analysis, ResMed stock appears to be undervalued. The current stock price of MXN4,082.00 is trading 14.2% below its estimated GF Value™ of MXN4,760.23. GuruFocus considers ResMed to be Modestly Undervalued.

Key valuation signals for MEX:RMD:

  • Cyclically Adjusted FCF per Share: MXN106.14
  • GF Value™: MXN4,760.23 vs. price of MXN4,082.00 (14.2% below fair value)
  • GF Score™: 98/100 with 1 warning sign

No single metric tells the full story. See the MEX:RMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ResMed Business Description

Address 9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
98GF Score

Get the complete analysis for MEX:RMD

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN4,082.00
Price
MXN4,760.23
GF Value